Summary & Overview
HCPCS J0166: Epinephrine Injection (0.1 mg), Non-Equivalent to J0165
HCPCS Level II code J0166 denotes a 0.1 mg injection of epinephrine (bpi) that is not therapeutically equivalent to J0165. This code is used to report administration of a specific epinephrine formulation for acute treatment scenarios where a 0.1 mg dose is indicated. Nationally, accurate coding of epinephrine injections matters for clinical documentation, payer adjudication, and drug utilization tracking, particularly as multiple formulations and biosimilar distinctions exist.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of billing context for J0166, typical sites of service, and the clinical scenarios in which a 0.1 mg epinephrine injection is used. The publication also outlines common modifiers and operational considerations and summarizes available benchmarking and coverage themes relevant to national payers. If specific payer policy details or granular fee benchmarks are required, those items are noted as Data not available in the input.
This summary provides clinicians, coders, and policy analysts with the coding definition, service context, and the scope of payer coverage discussed, enabling clearer communication about epinephrine administration events and consistent reporting across care settings.
Billing Code Overview
HCPCS Level II code J0166 represents an injection of epinephrine (bpi), not therapeutically equivalent to J0165, 0.1 mg. This code is used to bill for the administration of a 0.1 mg epinephrine product identified as a biosimilar or brand-specific formulation distinguished from J0165.
Service Type: Drug administration (therapeutic injection)
Typical Site of Service: Outpatient clinic, physician office, emergency department, or other ambulatory settings where injectable medications are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual presenting to an urgent care, emergency department, or outpatient allergy clinic with signs of anaphylaxis or a history of severe allergic reactions requiring provision of epinephrine for immediate intramuscular administration. A common scenario: a patient experiences rapid-onset urticaria, angioedema, throat tightness, wheeze, hypotension, or lightheadedness after exposure to a known allergen (food, insect sting, medication). Clinical workflow includes rapid assessment of airway/breathing/circulation, documentation of symptoms and vital signs, preparation of the prefilled epinephrine syringe or autoinjector substitute billed as J0166 (epinephrine, 0.1 mg), administration intramuscularly (typically lateral thigh), monitoring for clinical response, and arranging observation or transfer as indicated. Documentation includes indication, time and route of administration, dose, lot number, and patient response. Supply, storage, and disposal documentation (including any wasted medication) may be required for billing and inventory control.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When a portion of the single-use epinephrine vial or syringe is discarded and documentation supports wastage |